April 8, 2020 04:03 PM EDTUpdated 04:30 PM

Did Gilead just lower the bar on crucial remdesivir trials for Covid-19? Switching endpoints, amping up trial size stir analysts' fears — and hopes

To say Gilead’s remdesivir is in the R&D spotlight would be one of the great understatements of the year.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Did Gilead just low­er the bar on cru­cial remde­sivir tri­als for Covid-19? Switch­ing end­points, amp­ing up tri­al size stir an­a­lyst­s' fears — and hopes